Iradimed Corp (IRMD) Given $16.00 Consensus Target Price by Analysts

Iradimed Corp (NASDAQ:IRMD) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $16.00 for the company and are anticipating that the company will post $0.06 EPS for the current quarter, according to Zacks. Zacks has also given Iradimed an industry rank of 163 out of 265 based on the ratings given to its competitors.

A number of research firms recently weighed in on IRMD. ValuEngine upgraded shares of Iradimed from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Roth Capital began coverage on shares of Iradimed in a report on Tuesday, October 31st. They issued a “buy” rating and a $16.00 target price on the stock. Credit Suisse Group began coverage on shares of Iradimed in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th.

In other Iradimed news, Director Monty K. Allen sold 1,898 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $13.95, for a total value of $26,477.10. Following the completion of the sale, the director now owns 9,062 shares in the company, valued at approximately $126,414.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 60.10% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Ameriprise Financial Inc. increased its stake in Iradimed by 32.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 456,810 shares of the medical equipment provider’s stock valued at $4,386,000 after buying an additional 113,190 shares during the last quarter. Menta Capital LLC increased its stake in Iradimed by 5.7% in the 2nd quarter. Menta Capital LLC now owns 70,476 shares of the medical equipment provider’s stock valued at $606,000 after buying an additional 3,823 shares during the last quarter. Federated Investors Inc. PA grew its position in shares of Iradimed by 7.5% during the 2nd quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock valued at $347,000 after acquiring an additional 2,807 shares during the period. Connors Investor Services Inc. grew its position in shares of Iradimed by 10.0% during the 2nd quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock valued at $284,000 after acquiring an additional 3,000 shares during the period. Finally, Neuberger Berman Group LLC grew its position in shares of Iradimed by 23.3% during the 2nd quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 3,500 shares during the period. Hedge funds and other institutional investors own 13.83% of the company’s stock.

Shares of Iradimed (IRMD) traded down $0.25 during midday trading on Wednesday, hitting $15.25. 23,100 shares of the stock traded hands, compared to its average volume of 31,770. Iradimed has a 52-week low of $7.85 and a 52-week high of $15.85. The firm has a market capitalization of $163.61, a price-to-earnings ratio of 117.32 and a beta of 1.62.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.35. Iradimed had a net margin of 6.51% and a return on equity of 4.58%. The firm had revenue of $5.69 million for the quarter, compared to analyst estimates of $5.60 million. During the same quarter in the prior year, the business earned $0.14 earnings per share. The business’s quarterly revenue was down 25.9% compared to the same quarter last year. equities research analysts anticipate that Iradimed will post 0.05 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Iradimed Corp (IRMD) Given $16.00 Consensus Target Price by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/17/iradimed-corp-irmd-given-16-00-consensus-target-price-by-analysts.html.

About Iradimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get a free copy of the Zacks research report on Iradimed (IRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply